TruScreen has provided an update on its key markets and revenue guidance.
The company has signed a memorandum of understanding with Hangzhou Dalton Bioscience to expand its HPV product offerings.
In Vietnam, the launch of the Ho Chi Minh City Public Health Association screening program has been confirmed for April 12, 2025.
TruScreen also announced the appointment of an Indonesian distributor, with commercial sales expected to begin in April 2025.
In Uzbekistan, product registration is due in March 2025, which will enable the evaluation of TruScreen for a national screening program.
However, the company expects revenue for the financial year ended March 31, 2025, to be around $1.7 million, down from $2.1m in the previous year.
The planned screening programs in Zimbabwe and Vietnam have been delayed, and the timing of revenues from the delayed commercial activities will be reported in the first half of the 2026 financial year.
See more
